What did Drug Eluting Stents do with the accumulated wisdom?
ARTS-2 Trial evaluated patients with multivessel coronary artery disease undergoing coronary angioplasty with stenting drug eluting stents). 607 patients with multivessel coronary lesions (26.2% diabetic 54% 3 vessel disease 13.9% type C lesions) received sirolimus-eluting stents with average of 3.7 stents per patient with an average total length: 73 mm. Historical Controls from ARTS-1 were used for comparison: 1205 patients with multivessel coronary lesions (18.2% diabetic, 28% 3 vessel disease 7.5% type C lesions). At one year, there was no difference in event-free survival between the ARTS-2 SES group and the ARTS-1 CABG group. However, the ARTS-2 group showed significantly higher rates of survival free from cardiac death, MI, and reintervention than the ARTS-1 bare metal stent group. The groups were not significantly different in the primary endpoint of survival free from MACE. Among patients with multivessel coronary lesions, patients treated with sirolimus eluting stents (ARTS-2)
